NCT06427941 2026-04-17
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
BeOne Medicines
Phase 1 Recruiting
BeOne Medicines
AstraZeneca
Beijing Biotech
Aptamer Sciences, Inc.
Myeloid Therapeutics